Research article · 2011
Review articlePublished 25 Sep 2011
Tick-borne Encephalitis Vaccines
PanThera Biopharma, Aiea, HI; NIAID Integrated Research Facility, Ft. Detrick, Frederick MD
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Tick-borne encephalitis (TBE) is a disease that is found from western Europe across Asia and into Japan. In recent years the incidence rate has been increasing as has the endemic range of the virus. Tick-borne encephalitis is caused by three genetically distinct sutypes of viruses within a single TBE virus (TBEV) serocomplex. These three subtypes consist of Far-eastern subtype TBEV (TBEV-FE), Siberian subtype (TBEV-Sib) and European subtype (TBEV-Eu). Each of these subtypes cause clinically distinct diseases with varying degrees of severity. Development of the first vaccines for TBEV began in the late 1930s shortly after the first isolation of TBEV-FE in Russia. In the 1970s Austria began large scale vaccine production and a nationalized vaccine campaign that significantly reduced the incidence rate of TBE. Currently there are four licensed TBE vaccines, two in Europe and two in Russia. These vaccines are all quite similar formalin-inactivated virus vaccines but the each use a different virus strain for production. Published studies have shown that European vaccines are cross-protective in rodent studies and elicit cross-reactive neutralizing antibody responses in human vaccines. European vaccines have been licensed for a rapid vaccine schedule that could be used in response to a significant outbreak and reasonable neutralizing antibody titers can be achieved after a single dose although a second dose provides nearly complete and long-lasting protection. This review focuses on the current status of licensed TBE vaccines and provides a brief summary of technology currently being developed for new vaccines.
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 3 Jan 2024
Tick-borne Encephalitis: Understanding the Neurological Impact of Tick-borne Infections for Medical Diagnosis
Short communication · 2 Mar 2022
Determining the Hydrolysis Cycle of Tick-Borne Encephalitis Virus Helicase
Case report · 29 Oct 2015
Reversible Splenial Lesion Syndrome (RESLES) in a Patient with Clinically Mild Tick-Borne Encephalitis and Hyponatremia
Brief report · 26 Dec 2024
The Rising Threat of Tick-borne Encephalitis in Europe and Asia
More from this journal
The newest in Journal of Bioterrorism & Biodefense.
Editorial · 10 Dec 2025
Advanced Biodefense: Detection, Prevention, Preparednes
Case report · 10 Dec 2025
CRISPR: Enhancing Plant Resistance for Sustainability
Editorial · 10 Dec 2025
Adaptive Global Biodefense Against Future Threats
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioterrorism & Biodefense
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Axel T Lehrer”
- BylineArticles whose byline prints “Michael R. Holbrook”
